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OBJECTIVE—Type 2 diabetes results from a combination of
insulin resistance and impaired insulin secretion. To directly
address the effects of hepatic insulin resistance in adult animals,
we developed an inducible liver-speciﬁc insulin receptor knock-
out mouse (iLIRKO).
RESEARCH DESIGN AND METHODS—Using this approach,
we were able to induce variable insulin receptor (IR) deﬁciency
in a tissue-speciﬁc manner (liver mosaicism).
RESULTS—iLIRKO mice presented progressive hepatic and
extrahepatic insulin resistance without liver dysfunction. Ini-
tially, iLIRKO mice displayed hyperinsulinemia and increased
-cell mass, the extent of which was proportional to the deletion
of hepatic IR. Our studies of iLIRKO suggest a cause-and-effect
relationship between progressive insulin resistance and the fold
increase of plasma insulin levels and -cell mass. Ultimately, the
-cells failed to secrete sufﬁcient insulin, leading to uncontrolled
diabetes. We observed that hepatic IGF-1 expression was en-
hanced in iLIRKO mice, resulting in an increase of circulating
IGF-1. Concurrently, the IR-A isoform was upregulated in hyper-
plastic -cells of iLIRKO mice and IGF-1–induced proliferation
was higher than in the controls. In mouse -cell lines, IR-A, but
not IR-B, conferred a proliferative capacity in response to insulin
or IGF-1, providing a potential explanation for the -cell hyper-
plasia induced by liver insulin resistance in iLIRKO mice.
CONCLUSIONS—Our studies of iLIRKO mice suggest a liver-
pancreas endocrine axis in which IGF-1 functions as a liver-
derived growth factor to promote compensatory pancreatic islet
hyperplasia through IR-A. Diabetes 58:820–828, 2009
T
ype 2 diabetes results from a combination of
insulin resistance and impaired insulin secretion.
Although there is some debate about the primary
defect underlying type 2 diabetes, insulin resis-
tance is the most relevant pathophysiological feature of
the pre-diabetes state (1,2). Rodent studies have shown
that insulin insensitivity in both classic and nonclassic
insulin target tissues can play a role in the control of
glucose homeostasis (3). Insulin resistance also produces
a compensatory increase in insulin secretion generating
hyperinsulinemia, and ultimately, it is the failure of the
-cell that causes fasting hyperglycemia and development
of type 2 diabetes (1). Several mouse models have been
developed to study the contributions of insulin resistance
in various tissues to the overall regulation of glucose
homeostasis (4). Although total whole-body insulin resis-
tance produced by complete deletion of the insulin recep-
tor (IR) does not produce any major effect on mouse
development, these mice die 1 week after birth from
severe ketosis (5,6). Combined restoration of IR function
in brain, liver, and pancreatic -cells rescues IR knockout
mice from neonatal death, prevents diabetes in a majority
of animals, and normalizes adipose tissue content, lifes-
pan, and reproductive function. In contrast, mice with IR
expression limited to brain or liver and pancreatic -cells
are rescued from neonatal death but develop lipoatrophic
diabetes and die prematurely (7).
Based on studies using tissue-speciﬁc conditional
knockout of IR, liver, brain, and -cells represent the key
sites of insulin resistance in the development of type 2
diabetes (8–10). The liver-speciﬁc IR knockout (LIRKO)
revealed that insulin resistance in liver is the most impor-
tant for development of impaired glucose tolerance and
fasting hyperglycemia. In addition, these mice also devel-
oped marked -cell hyperplasia, hyperinsulinemia, and
decreased insulin clearance (8). With aging, however, the
diabetes in these animals was corrected, suggesting some
form of compensatory mechanism possibly linked to the
very early onset of insulin resistance in these mice that
limited understanding of the full impact of hepatic insulin
resistance in the pathogenesis of type 2 diabetes. More-
over, these mice developed liver damage related to appear-
ance of hyperplastic nodules that might have altered
glucose production by the liver, leading to regression of
the diabetic state with aging (8). To better address the role
of adult hepatic insulin resistance in the pathogenesis of
type 2 diabetes, we developed an inducible model for
generating liver IR deﬁciency (iLIRKO) in young, weaned
mice.
RESEARCH DESIGN AND METHODS
IR
(loxP/loxP) C57Bl/6 mice were created by homologous recombination using an
IR gene targeting vector with lox P sites ﬂanking exon four as previously
described (11). Transgenic mice expressing a Cre recombinase transgene
under the control of the Mx1 promoter/enhancer were purchased from
Jackson Laboratory (Bar Harbor, ME). The IR
(loxP/loxP) mice were crossed
with Mx-Cre mice to obtain iLIRKO mice. After weaning, iLIRKO mice were
injected intraperitoneally with poly-inositic-poly-cytidilic acid (500 g/injec-
tion) to induce the interferon- response and the consequent Mx1 promoter
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820 DIABETES, VOL. 58, APRIL 2009activation as described previously with minor modiﬁcations (12). Animals
were housed in virus-free facilities on a 12-h light-dark cycle (on at 0700 h, off
at 1900 h) and were fed with a standard rodent chow ad libitum. All animal
experimentation described in this article was conducted in accordance with
accepted standards of humane animal use as approved by the corresponding
institutional committee.
Genotyping of the IR
(loxP/loxP) transgenic mice. IR
(loxP/loxP) transgenic
mice were genotyped by PCR. Tail DNA (100–200 ng) was ampliﬁed 30 cycles
(40 s, 94°C; 40 s, 60°C; and 1 min, 75°C) by a thermal cycler. Two primers
ﬂanking the loxP site behind exon four of the IR were used: the forward
primer (5-GATGTGCACCCCATGTCTG-3) and the reverse primer (5-CT-
GAATAGCTGAGACCACAG-3). A 320-bp band was obtained for the ﬂoxed
allele or a 280-bp band for the wild-type allele.
Genotyping of the Mx1-Cre transgenic mice. Mx1-Cre transgenic mice
were genotyped by PCR. Tail DNA (100–200 ng) was ampliﬁed 35 cycles (1
min, 94°C; 1 min, 60°C; and 1 min, 72°C) on a thermal cycler. To amplify the
Mx1-Cre transgene (PCR product, 269 bp), primers SF-4 (5-GCATAACCAGT-
GAAACAGCATTGCTG-3) and 69R (5-GGACATGTTCAGGGATCGCCAG-
GCG-3) were used.
Western blot analysis. Tissues were homogenized as described (11). West-
ern blot analyses of insulin signaling proteins were performed on liver,
muscle, brown adipose tissue, and brain homogenates as previously described
(13). The antibodies used were anti-IR (Ab-4) from Oncogene (San Diego,
CA), anti-PEPCK antibody provided by D.K. Granner (Vanderbilt University,
Nashville, TN), anti-glucokinase antibody (a gift of S. Lenzen, Hannover
Medical School, Hannover, Germany), anti–fatty acid synthase antibody
(purchased from BD Transduction Laboratories, San Diego, CA), and anti–-
actin antibody (Sigma-Aldrich, St. Louis, MO). Anti–IGF-1 antibody was
purchased from Upstate Biotechnology (Lake Placid, NY). Anti–phospho-p70-
S6-kinase (Thr 421/Ser 424), anti–phospho-p44/p42-MAPK (Thr202/Tyr204),
anti–phospho-Akt (Ser 473) antibodies were purchased from Cell Signaling
(Beverly, MA). For in vivo insulin signaling studies, mice were injected with 1
unit/kg body wt of human insulin (Novo Nordisk) into the peritoneal cavity.
After 10 min, tissues were removed and immediately frozen in liquid nitrogen.
Triplicate blots of samples from ﬁve individuals of each genotype were used.
Densitometric analysis was performed using a GS-710 Imaging Densitometer,
and signals were quantiﬁed using Quantity One software (Bio-Rad Laborato-
ries, Hercules, CA).
Analytical procedures. Insulin levels in serum were measured by RIA using
mouse insulin as a standard (Linco Research, St. Charles, MO). Radioimmu-
noassay using mouse IGF-1 as a standard (Diagnostic Systems Laboratories,
Webster, TX) measured IGF-1 levels in serum. Glucose tolerance and insulin
tolerance tests were performed as previously described (14).
Histological analysis. The immunohistochemical analysis of pancreata was
performed as described (14). -Cell mass was evaluated by point-counting
morphometry (15,16). Relative volumes were calculated for -cells, non–-
cells, and exocrine tissue. Contaminating tissue (including adipose, lymph
nodes, and intestines) was recorded to correct for the pancreatic weight. The
-cell mass was then calculated by multiplying the relative -cell volume by
the corrected pancreatic weight. Staining of liver sections with hematoxylin/
eosin, periodic acid Schiff, and Masson reagents was performed using standard
techniques.
Real-time quantitative PCR for insulin receptor isoforms. The pancre-
atic islets were isolated from 6-month-old control and iLIRKO mice as
previously described (10). Insulin receptor isoforms expression in isolated
islets was analyzed by real-time quantitative PCR using Taqman probes (MGB
“Assay on Demand” probes; Applied Biosystems) following the manufactur-
er’s instructions. The comparative threshold cycle (Ct) method was used to
calculate the relative expression. For quantiﬁcation of gene expression, the
target genes values were normalized to the expression of the endogenous
reference (18S). Thus, the amount of target, normalized to 18S and relative to
the control, is given by 2
Ct [Ct  Ct (target gene)  Ct (18S); Ct  Ct
for any sample  Ct for the control].
Reconstitution of IRKO immortalized -cells with IR-A or -B isoforms
by retroviral infection. IRKO -cells were generated in our laboratory as
previously described (17). From these cells we reconstituted and character-
ized the expression of the IR-A isoform (Rec A) and IR-B isoform (Rec B)
generating new cell lines as previously described (18).
Measurement of glucose uptake in -cells. Cells were cultured to 80%
conﬂuence in 10% FBS-DMEM and then serum and glucose starved for 4–6 h.
After that, 10 nmol/l insulin or 10 nmol/l IGF-1 were added to the wells for 30
min. Glucose uptake was measured by incubating cells with 2-deoxy-D-[1-
3H]-
glucose for the last 10 min in triplicate dishes from six independent experi-
ments as previously described (19).
Cell viability assays. Cells were plated in 12-multiwell plates and cultured in
10% FBS-DMEM until 40–50% of conﬂuence was reached. Cells were deprived
of serum for a minimum of 4 h and then treated with insulin (10 nmol/l), IGF-1
(10 nmol/l), or both for 24 h. Subsequently, the cells were washed with PBS
and stained with violet crystal as described (17).
Proliferation studies in isolated pancreatic islets and cultured -cells.
DNA synthesis in isolated islets was estimated by determining BrdU incorpo-
ration using the Cell Proliferation ELISA kit (Roche Diagnostics, Mannheim,
Germany). In cultured -cells, the DNA synthesis was estimated by [
3H]
thymidine incorporation into trichloroacetic acid–precipitable material as
previously described (20).
All values are expressed as means  SEM. Data were compared by ANOVA
with the Bonferroni post-test or the Student’s t test. The level of signiﬁcance
was set at P 	 0.05.
RESULTS
Progressive liver-speciﬁc insulin receptor deletion
without liver dysfunction. To create an inducible liver-
speciﬁc deletion of the IR, IR
(loxP/loxP) mice (11) were bred
with transgenic mice expressing a Cre recombinase trans-
gene under the control of the Mx1 promoter/enhancer.
Finally, we obtained mice that all carried two ﬂoxed IR
alleles and were heterozygous for the Mx1-Cre transgene.
Thus, these mice constituted the iLIRKO mouse strain.
Given that the deletion of IR varied from 
50–100%, mice
were divided into three groups: ones with 
50% of the
normal receptor expression, a second group with mice
bearing 
25% of normal IR, and a third group containing
mice with virtually no remaining IR. Ablation of IR was
tissue speciﬁc because none of the other insulin target
tissues was affected (results not shown). An important
feature of the phenotype produced by fetal IR deletion
(LIRKO) was the appearance of liver dysfunction and
histological changes. However, hematoxylin-eosin staining
in liver sections revealed no dysplastic or hyperplastic
nodules in 6- and 12-month-old iLIRKO mice as compared
with their respective controls. In addition, Masson staining
showed no increase in collagen inﬁltration or ﬁbrosis in
iLIRKO mice (Fig. 1, upper panels). Regarding enzymes of
hepatic glucose metabolism, postnatal deletion of IR
caused a reduction of glucokinase protein expression and
a dramatic loss of glycogen liver content in iLIRKO mice
consistent with previous observations in the LIRKO model
(8). However, the expression of phosphoenol pyruvate
carboxykinase or fatty acid synthase genes in 6-month-old
mice was unchanged in iLIRKO mice as compared with
controls (Fig. 1, lower panels).
Progressive insulin resistance and glucose intoler-
ance in iLIRKO. In LIRKO mice, insulin signaling in vivo
is selectively impaired in liver because these mice display
normal insulin sensitivity in skeletal muscle (8). At 6
months of age, iLIRKO mice presented defects in insulin
signaling, which were proportional to their loss of IR
expression. Thus, in the group with 50% reduction in IR
expression, there was a marked decrease in Akt, extracel-
lular signal–related kinases (ERKs), and p70S6-kinase ac-
tivation, whereas in the group with complete IR deletion,
insulin was unable to activate these signaling pathways
(Fig. 2). Interestingly, although our deletion strategy did
not alter the levels of IR expression in other tissues
(results not shown), we observed progressive impairment
of insulin signaling in some peripheral tissues. Thus, in
iLIRKO mice, there was a graded impairment of insulin-
stimulated Akt and ERKs signaling in brain, skeletal mus-
cle, or interscapular brown adipose tissue, the degree of
which correlated with the severity of IR deletion in the
liver (Fig. 2). Similarly, p70S6-kinase signaling was im-
paired in response to insulin in these tissues and was
dependent as well on hepatic IR expression. Insulin sig-
naling in both liver and these extrahepatic tissues was
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shown). Our results indicate that the iLIRKO mouse de-
velops primary insulin resistance in the liver, and this is
associated with secondary insulin resistance in peripheral
tissues, which persists throughout the life of the animal. In
conventional LIRKO mice, IR deletion induced severe
insulin resistance, which caused glucose intolerance at 2
months of age, but this diabetic phenotype was completely
reversed by 6 months of age when these mice presented
normal glucose tolerance (8). In contrast, our strategy of
deleting the IR after weaning induced progressive insulin
resistance in iLIRKO mice from 2 to 6 months old and this
persisted at 1 year of age (Fig. 3, upper panels). More
importantly, the mice without liver IR displayed progres-
sive glucose intolerance and even developed fasting hy-
perglycemia at 1 year of age (Fig. 3, lower panels).
Progressive -cell hyperplasia and failure of insulin
secretion with aging. Previously, it was shown that
constitutive LIRKO mice developed severe hyperinsulin-
emia and -cell hyperplasia by 2 months of age, and this
fasting hyperinsulinemia remained unchanged although
the glucose intolerance reverted with aging (8). In the
present study, iLIRKO presented progressive -cell hyper-
plasia as compared with controls. More importantly, the
level of hyperplasia was correlated to the level of IR
expression in the liver (Fig. 4B). The iLIRKO mice also
developed progressive hyperinsulinemia as compared with
controls, and this also correlated with the extent of IR
deletion in the liver (Fig. 4B). This -cell expansion
persisted throughout life as shown in Fig. 4D. In parallel,
plasma insulin increased by 2.5-fold in 1-year-old mice as
compared with their controls (Fig. 4D); however, this
increase was much lower than at 6 months of age
(threefold, Fig. 4D), suggesting a failure of insulin secre-
tion with aging. Additionally, insulin content in pancreas
slides of 6-month-old and 1-year-old iLIRKO mice was
quantiﬁed. The data revealed a 25% increase in the insulin
content (P 	 0.0001) in 1-year-old as compared with
6-month-old iLIRKO mice (results not shown).
Progressive hepatic expression and plasma concen-
tration of IGF-1 in iLIRKO mice. Previous studies have
suggested the presence of a circulating islet growth
factor in insulin-resistant states independent of glucose
and obesity (21). To address this important issue, we
performed Western blot analysis of iLIRKO liver sam-
ples using anti–IGF-1 antibodies. We observed increases
of IGF-1 expression that depended inversely on the level
of IR expression in the liver (Fig. 4A). In parallel,
IGFBP1 and IGFBP3 were also upregulated in iLIRKO
mice depending on the extent of IR deletion in liver.
These data were conﬁrmed in 1-year-old mice (Fig. 4C).
Interestingly, iLIRKO mice, which expressed no liver IR,
s
FIG. 1. Liver histology and metabolic gene expression in inducible liver-speciﬁc insulin receptor knockout (iLIRKO) mice. A: Periodic acid Schiff,
hematoxylin-eosin (H/E), and Masson staining of liver sections from fed 6- and 12-month-old male control (upper panel) and iLIRKO (lower
panel) mice. The images are representative of four independent experiments. Magniﬁcations 20. B: Protein extracts of liver from 6-month-old
Wt (wild type), IR
(loxP/loxP), and iLIRKO mice were analyzed by Western blot (WB) with anti-IR -chain, PEPCK, FAS (fatty acid synthase), GK,
and -actin antibodies as indicated in each panel. The blots are representative of ﬁve independent experiments. The corresponding
autoradiograms were quantitated by scanning densitometry and are expressed as mean  SEM. (A high-quality digital representation of this
ﬁgure is available in the online issue.)
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months and 1 year of age as compared with controls
(Fig. 4B and D, respectively).
Increase of IR-A isoform in pancreatic islets: -cell
lines expressing IR-A, but not IR-B, induce prolifer-
ation in response to insulin or IGF-1. The IR expres-
sion in pancreatic islets, as estimated by real-time PCR,
signiﬁcantly increased in iLIRKO mice as compared with
controls (Fig. 5A). More importantly, the percentage of
IR-A isoform (IR-A) expressed in pancreatic islets dramat-
ically increased in iLIRKO mice as compared with controls
(Fig. 5A). To assess whether the balance of IR-A versus
IR-B might alter the proliferation rate of islets, we ana-
lyzed BrdU incorporation in response to either 10 nmol/l
insulin or 10 nmol/l IGF-1 in pancreatic islets of 6-month-
old mice. The results demonstrated that IGF-1–induced
proliferation was signiﬁcantly higher in pancreatic islets
from iLIRKO mice than in the controls (Fig. 5B). Previous
reports suggest that IR-A was twofold more sensitive than
IR-B in mediating glycogen synthesis and mitogenesis (22).
To further explore these possibilities in mouse -cells, we
generated -cell lines bearing IR (IRLoxP), lacking IR
(IRKO), expressing exclusively IR-A (Rec A), or express-
ing exclusively IR-B (Rec B) (Fig. 5C). Cell lines express-
ing IR responded to 10 nmol/l insulin in contrast to cells
lacking IR as determined by Western blot analysis of IR
phosphorylation (Fig. 5D). Additionally, the four cell lines
responded to 10 nmol/l IGF-1 as conﬁrmed by IGF-1R
phosphorylation (Fig. 5D). The lack of IR signiﬁcantly
decreased basal glucose uptake in -cells. Reconstitution
with IR-A, but not with IR-B, restored basal glucose uptake
to levels higher than those observed in control cells (Fig.
5E). Although either insulin or IGF-1 enhanced cell viabil-
ity in control cells, only IGF-1 induced cell viability in
-cells lacking IR. Rec A cells but not Rec B increased cell
viability in response to either insulin or IGF-1 (Fig. 5F).
When we assessed proliferation by thymidine incorpo-
ration, both insulin and IGF-1 increased proliferation in
control -cells, whereas cell lines lacking IR did not
respond to IGF-1. Finally, insulin and IGF-1 promoted
proliferation in Rec A -cells but not in Rec B lines (Fig.
5G).
DISCUSSION
Insulin promotes both metabolism and growth in the liver.
Constitutive ablation of IR in liver causes severe metabolic
changes and a reduction of liver size by 
50% (8). Like-
wise, mice in which there is variable IR deletion (cellular
mosaicism) exhibit different degrees of growth retardation
and metabolic abnormality depending on the extent of IR
deletion. IR ablation in 
80% of cells causes extreme
growth retardation and lipoatrophy with -cell hyperpla-
sia, whereas IR ablation in 98% of cells, although resulting
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FIG. 2. Inducible liver-speciﬁc insulin receptor knockout (iLIRKO) shows insulin resistance in the liver and extrahepatic tissues. In vivo insulin
signaling studies were performed in 6-month-old control and iLIRKO mice. Mice of both experimental groups were injected with 1 unit/kg body wt
of human insulin (Novo Nordisk) into the peritoneal cavity. After 10 min of treatment, liver, muscle, BAT (brown adipose tissue), and brain were
removed. Protein extracts of these tissues were analyzed by Western blot (WB) with anti-IR -chain, phospho-Akt, phospho-p70, phospho-ERK1/2,
and -actin antibodies. The results are representative of four independent experiments. Histograms summarize the densitometric analysis of the
corresponding Western blots.
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diabetes without -cell hyperplasia (23). These ﬁndings
suggest that insulin regulates growth independently of
metabolism and that the number of insulin receptors is an
important determinant of the speciﬁcity of insulin action.
In the present study, we have used an inducible strategy to
generate IR deﬁciency in liver; thus, we obtained mice
with variable levels of IR deletion (liver mosaicism). Based
on this iLIRKO model, induction of liver IR deﬁciency after
weaning caused progressive insulin resistance and glucose
intolerance without alterations in liver growth. Under our
experimental conditions, the effects of insulin on growth
and metabolic regulation are mutually independent. Thus,
deletion of liver IR in young adults gave rise to irreversible
insulin resistance and progressive glucose intolerance,
which persisted for up to 1 year, although liver damage
was not observed in any iLIRKO mice.
Previous studies with conditional knockouts and recon-
stitution models concluded that the progression of insulin
resistance to diabetes with fasting hyperglycemia requires
defects in tissues other than liver (7,8). Moreover, acute
deletion of IR in the liver has been reported to impair
insulin signaling but does not induce insulin resistance or
hyperinsulinemia (24). Our results in iLIRKO demonstrate
that liver-speciﬁc disruption of IR can impair both hepatic
and extrahepatic insulin signaling and that the severity of
this resistance depends on the extent of IR deletion in the
liver. iLIRKO mice display early insulin resistance as a
primary defect related directly to the reduction or ablation
of liver IR, but they also have impaired insulin signaling in
other peripheral tissues, including skeletal muscle and
brain. Thus, iLIRKO mice present systemic insulin resis-
tance as a secondary effect. Given that our deletion
strategy did not alter IR expression in other tissues, this
effect is likely the result of desensitization of the IR in
extrahepatic tissues produced by prolonged hyperinsulin-
emia. Thus, our results demonstrate that a primary defect
in the liver triggers secondary insulin resistance in extra-
hepatic tissues and suggest that the progression to diabe-
tes in iLIRKO mice does not require defects other than
liver IR deﬁciency.
Insulin resistance is associated with hyperinsulinemia
and leads to -cell hyperplasia. Thus, total deletion of liver
IR induced -cell hyperplasia in LIRKO animals (8). How-
ever, conditional inactivation of IR in muscle was not
associated with either islet hyperplasia or elevated circu-
lating levels of insulin (11). Our results with iLIRKO
demonstrate a direct relationship between the level of IR
expression remaining in the liver and the fold increase of
plasma insulin levels and -cell mass. Finally, constitutive
LIRKO mice displayed dysregulation of insulin secretion
for more than 1 year. However, in iLIRKO mice, compen-
satory hyperinsulinemia in 1-year-old mice was much
lower than in 6-month-old mice. Thus, in our model, a
failure in insulin secretion by -cells seems to occur given
the inhibition of insulin clearance in the liver, the major
site where insulin is degraded in an IR-dependent manner
(25). More importantly, the observations from iLIRKO
FIG. 3. Progressive insulin resistance and glucose intolerance in inducible liver-speciﬁc insulin receptor knockout (iLIRKO) mice. A: Insulin
tolerance tests were performed on 2-, 4-, 6-, and 12-month-old male control (E) and iLIRKO (F) mice. Fed animals were injected intraperitoneally
with 1 unit/kg body wt of human regular insulin. Blood glucose was measured immediately before injection and 15, 30, and 60 min after the
injection. Results expressed as percentage of initial blood glucose concentration are means  SEM (n  10–20). B: Glucose tolerance tests were
performed on 2-, 4-, 6-, and 12-month old control (E) and iLIRKO (F) mice that had been fasted for 16 h. Animals were injected intraperitoneally
with 2 g/kg body wt of glucose. Blood glucose was measured immediately before injection and 30, 60, 90, and 120 min after the injection. Results
are expressed as mean blood glucose concentration  SEM; n  10–20 of each genotype. **P < 0.005; *P < 0.05; iLIRKO versus control.
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longed hypersecretion of insulin, the -cells ultimately
undergo a failure to secrete insulin.
Previous evidence demonstrated that insulin signaling is
essential for -cell growth (10,26). Recently, double deﬁ-
ciency for IR in the liver and the -cells was unable to
induce -cell hyperplasia in response to severe insulin
resistance (27). In fact, the persistence of robust hyper-
plasia in 6-month-old hypoglycemic LIRKO mice supports
the concept of a glucose-independent circulating islet
growth factor (27). In this context, iLIRKO mice displayed
increased liver IGF-1 expression dependent on the extent
of IR deletion in the liver. This resulted in a persistent
increase of plasma IGF-1, consistent with the fact that the
liver is the main source of circulating IGF-1 (28). Previous
data demonstrated that conditional deletion of IGF-1R in
the -cell does not alter islet -cell mass growth, suggest-
ing a role for this receptor in regulating differentiated
function (29). Surprisingly, we have found a relationship
between hyperinsulinemia and -cell hyperplasia based on
an increase of genes related to -cell proliferation and
differentiation in iLIRKO mice. Thus, IGF-1 signaling might
be involved in the induction of genes related to glucose-
stimulated insulin secretion, among others. IGFBPs regu-
late the systemic effects of IGF-1 in a complex manner
(30). Interestingly, IGFBP1 was upregulated in parallel to
IGF-1 in iLIRKO mice, effects that were dependent on the
level of hepatic IR deletion. These results are entirely
consistent with the insulin-mediated effect on the IGFBP1
gene expression in liver cells (31). IGFBP1, which is
mainly produced by the liver in the adult mice, inhibits
IGF-dependent cellular growth in vivo (30,32,33). In addi-
FIG. 4. Progressive IGF-1 liver expression, -cell hyperplasia, and defective insulin secretion with aging in inducible liver-speciﬁc insulin receptor
knockout (iLIRKO). A: Liver extracts from 6-month-old control and iLIRKO mice with graded IR deletion were analyzed by Western blot with
anti-IR -chain, IGF-1, IGFBP1, IGFBP3, and -actin antibodies. The Western blot autoradiograms of IGF-1 were quantiﬁed by scanning
densitometry from four independent experiments. B, upper panel: -cell mass was evaluated by point-counting morphometry in 6-month-old
control () and iLIRKO mice (mice with 50% IR, `; mice with 25% IR, z; mice with 0% IR, f), results shown as fold increase of -cell mass in
control animals, n  7–15 of each group. Lower left panel: plasma insulin content was measured in 6-month-old male control () and iLIRKO mice
(50% IR, `; 25% IR, z;0 %I R ,f) by RIA (Linco); values are expressed as means  SEM from four animals per genotype. Lower right panel: plasma
IGF-1 content was measured in 6-month-old male control () and iLIRKO mice (50% IR, `; 25% IR, z;0 %I R ,f) by RIA (Diagnostic Systems
Laboratories). Values expressed as mean  SEM from four animals per genotype. C: Liver extracts from 1-year-old control and iLIRKO mice were
analyzed by Western blot with anti-IR -chain, IGF-1, IGFBP1, IGFBP3, and -actin antibodies. A representative experiment out of four is shown.
D, upper panel: -cell mass was evaluated by point-counting morphometry in 1-year-old control and iLIRKO mice; results are presented as fold
increase of the control -cell mass. Lower left panel: plasma insulin content was measured in 1-year-old male control and iLIRKO mice by RIA
(Linco); values are expressed as means  SEM from four animals per genotype. Lower right panel: plasma IGF-1 content was measured in
1-year-old male control and iLIRKO mice by RIA (Linco); values are expressed as means  SEM from four animals per genotype.*P < 0.05, **P <
0.005, and ***P < 0.001 iLIRKO versus control.
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and fasting hyperglycemia and hyperinsulinemia. How-
ever, the hyperinsulinemia observed in IGFBP1 transgenic
mice cannot be attributable to insulin resistance alone
(34,35). In fact, adult IGFBP1 transgenic mice displayed
larger and more numerous -cell islets reﬂecting increased
-cell proliferation (36). The increase of plasma IGF-1 and
IGFBP1 in iLIRKO mice contrasts with IGF-1 decreases
and IGFBP1 increases in liver-speciﬁc Irs1
/:Irs2
/
mice, a mouse model also showing -cell mass hyperplasia
(37). Finally, the levels of IR were increased in the
pancreatic islets of iLIRKO as compared with controls.
Moreover, we noted an increase in the expression of IR-A
versus IR-B in pancreatic islets from iLIRKO mice. Under
our experimental conditions, IGF-1-induced proliferation
was signiﬁcantly higher in pancreatic islets from iLIRKO
FIG. 5. Increase of IR-A isoform in pancreatic islets: -cell lines expressing IR-A (Rec A), but not IR-B (Rec B), induce proliferation in response
to insulin or IGF-1. A: mRNA levels of insulin receptor and the insulin receptor isoforms distribution were analyzed by real-time quantitative PCR
in 6-month-old control and iLIRKO mice as described in RESEARCH DESIGN AND METHODS. Values are expressed as mean  SEM; n  4 of each genotype,
(*P < 0.05; **P < 0.005; ***P < 0.001 iLIRKO vs. control). B: Pancreatic islet proliferation was assessed by BrdU incorporation in 6-month-old
control and inducible liver-speciﬁc insulin receptor knockout (iLIRKO) mice. The islets were isolated as described and seeded in 96-well plates
for 16 h in RPMI medium. After that, the medium was removed and fresh medium with the stimuli (10 nmol/l insulin, `; 10 nmol/l IGF-1, z) and
BrdU was added for 24 h. Finally, the BrdU incorporation was measured as indicated by the manufacturer. Values are expressed as mean  SEM;
n  4 of each genotype. Data were subjected to ANOVA with Bonferroni post-test (*P < 0.05; IGF-1 vs. basal in iLIRKO mice). C: IR expression
was analyzed by Western blot and RT-PCR in IRLoxP, IRKO, Rec A, and Rec B -cells. Arrow at the RT-PCR panels indicates the IR-A and IR-B.
A representative experiment out of four is shown. D: Functional assessment of insulin receptor reconstitution was carried out by immunopre-
cipitation of insulin– or IGF-1–stimulated -cells with antibodies against IR or IGF-1R and subsequent Western blot against phospho-tyrosine
residues. E: IRLoxP, IRKO, Rec A, and Rec B -cells were cultured to 80% conﬂuence and then serum and glucose starved for 4–6 h. Glucose
uptake induced by insulin (`) or IGF-1 (z) was measured as described in RESEARCH DESIGN AND METHODS. Data were subjected to ANOVA with
Bonferroni post-test (*P < 0.05, IRKO and Rec A vs. IRLoxP in basal conditions; #P < 0.05, IGF-1 vs. basal of each cell line). F: IRLoxP, IRKO,
Rec A, and Rec B -cells were cultured to 50% conﬂuence in 10% FBS-DMEM overnight. After that, 10 nmol/l insulin (`), 10 nmol/l IGF-1 (z),
or both (f) were added to the wells in serum-starved 5 mmol/l glucose DMEM. After 24 h, the medium was withdrawn and the four cell lines were
stained with violet crystal as described in RESEARCH DESIGN AND METHODS. Statistical signiﬁcance was carried out by Student’s t test by comparison
of basal conditions with insulin-stimulated conditions of each cell line (*P < 0.05) or basal conditions with IGF-1–stimulated conditions of each
cell line (#P < 0.05). G: IRLoxP, IRKO, Rec A, and Rec B -cells were cultured to 50% conﬂuence in 10% FBS-DMEM overnight. After that, 10
nmol/l insulin (`), 10 nmol/l IGF-1 (z), or both (f) were added to the wells in serum-starved 5 mmol/l glucose DMEM for 24 h. Thymidine
incorporation was measured in these conditions as described in RESEARCH DESIGN AND METHODS. Statistical signiﬁcance was carried out by Student’s
t test by comparison of basal conditions with insulin-stimulated conditions of each cell line (*P < 0.05) or basal conditions with IGF-1–stimulated
conditions of each cell line (#P < 0.05).
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notion that increased expression of IR-A relative to IR-B
may enhance the growth response of pancreatic -cell to
IGF-1. Moreover, based on our observations in mouse
-cell lines, the presence of mostly IR-A in pancreatic
islets may cause initially an increase in glucose uptake, a
classic mitogenic signal in -cells (17) and, subsequently,
enhanced proliferation in response to either insulin or
IGF-1. Alternatively, an increase in IRS-2 in pancreatic
islets from iLIRKO mice may account for their enhanced
proliferation in response to IGF-1. Our data obtained in
pancreatic islets microarrays from iLIRKO versus control
mice rule out that possibility (results not shown). Taken
all together, our ﬁndings imply that IR-A, but not IR-B,
confers a proliferative capacity to -cells, which enables
them to respond to insulin or IGF-1; this hypothesis may
account for the -cell hyperplasia induced by liver insulin
resistance in iLIRKO mice. Thus, our results in iLIRKO
mice seem to suggest a liver-pancreas endocrine axis,
whereby increased plasma IGF-1 functions as a liver-
derived growth factor to promote compensatory -cell
hyperplasia through IR-A.
In conclusion, our results demonstrate that hepatic IR
deﬁciency can lead to systemic insulin resistance. Given
that insulin resistance states can be compensated for by
-cell hyperplasia, studies of iLIRKO emphasize a cause-
and-effect relationship between progressive insulin resis-
tance and -cell hyperplasia. Ultimately, the -cells fail to
secrete sufﬁcient insulin, and this leads to uncontrolled
diabetes. Thus, in iLIRKO mice, hepatic insulin resistance
is sufﬁcient to recapitulate the progressive pathogenesis of
type 2 diabetes. IGF-1 expression was enhanced depend-
ing on the extent of hepatic IR deletion, and this resulted
in a persistent increase of circulating IGF-1 in iLIRKO
mice. Concurrently, IR-A expression was signiﬁcantly in-
creased in pancreatic islets of iLIRKO mice, presumably
providing a mechanism by which the proliferative re-
sponse to IGF-I was enhanced in the hyperplastic pancre-
atic islets of iLIRKO mice. Thus, our studies of iLIRKO
mice suggest a liver-pancreas endocrine axis in which
IGF-1 functions as a liver factor to promote compensatory
-cell hyperplasia through IR-A.
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